References
- Abrams, T. (2008). Warning Letter: YAZ® (drospirenone and ethinyl estradiol) Tablets. Food and Drug Administration. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/EnforcementActivitiesbyFDA/ WarningLettersand NoticeofViolationLettersto PharmaceuticalC ompanies/ucm053993.pdf
- American Marketing Association. (2013, July). Definition of marketing.https://www.ama.org/AboutAMA/Pages/Definition-of-Marketing.aspx
- Applbaum, K. (2006). Pharmaceutical marketing and the invention of the medical consumer. PLoS Medicine, 3(4), e189. https://doi.org/https://doi.org/10.1371/journal.pmed.0030189
- AstraZeneca. (2017). What science can do: AstraZeneca Annual Report and Form 20-F Information 2016.
- Bailey, M. J. (2010). “Momma’s Got the Pill”: How Anthony Comstock and Griswold v. Connecticut Shaped US Childbearing”. American Economic Review, 100(1), 98–129. https://doi.org/https://doi.org/10.1257/aer.100.1.98
- Bayer (2017). Annual Report 2016: Augmented Version.
- Bélisle-Pipon, J.-C. (2013). De la binarité au modèle AI3R : la bioéthique écosystémique comme modèle d’analyse normative de l’industrie biopharmaceutique. [Master Thesis]. Université de Montréal.
- Bélisle-Pipon, J.-C. (2016). Dear DTCA, please don’t deceive me, don’t. BioéthiqueOnline, 5(35). https://doi.org/https://doi.org/10.7202/1044293ar
- Bélisle-Pipon, J.-C. (2017). Les enjeux éthiques des communications directes aux patients par les compagnies pharmaceutiques [Université de Montréal]. http://hdl.handle.net/1866/20253
- Bélisle-Pipon, J.-C. (2020). Patients with “dates”: Wrong for doctors but acceptable for drug companies?Bioethics Update, 6(1), 7–16. https://doi.org/https://doi.org/10.1016/j.bioet.2019.07.002
- Bélisle-Pipon, J.-C., & Birko, S. (2017). Using social media to sell prescription drugs. Impact Ethics,
- Bélisle-Pipon, J.-C., & Williams-Jones, B. (2015a). Drug familiarization and therapeutic misconception via direct-to-consumer information. Journal of Bioethical Inquiry, 12(2), 259–267. https://doi.org/https://doi.org/10.1007/s11673-015-9634-8
- Bélisle-Pipon, J.-C., & Williams-Jones, B. (2015b). Regulating direct-to-consumer drug information: A case study of Eli Lilly’s Canadian 40over40 erectile dysfunction campaign. Healthcare Policy, 10(4), 16–23. https://doi.org/https://doi.org/10.12927/hcpol.2015.24209
- Bélisle-Pipon, J.-C., & Williams-Jones, B. (2016). Preparing for the arrival of “pink Viagra”: Strengthening Canadian direct-to-consumer information regulations. Canadian Medical Association Journal, 188(5), 319–320. https://doi.org/https://doi.org/10.1503/cmaj.150705
- Bhutada, N. S., & Rollins, B. L. (2015). Disease-specific direct-to-consumer advertising of pharmaceuticals: An examination of endorser type and gender effects on consumers’ attitudes and behaviors. Research in Social & Administrative Pharmacy, 11(6), 891–900. https://doi.org/https://doi.org/10.1016/j.sapharm.2015.02.003
- Biegler, P., & Vargas, P. (2016). Feeling is believing: Evaluative conditioning and the ethics of pharmaceutical advertising. Journal of Bioethical Inquiry, 13(2), 271–279. https://doi.org/https://doi.org/10.1007/s11673-016-9702-8
- Brody, H. (2012). The ethics of drug development and promotion: The need for a wider view. Medical Care, 50(11), 910–912. https://doi.org/https://doi.org/10.1097/MLR.0b013e31826c8767
- Brody, H., & Light, D. W. (2011). The inverse benefit law: How drug marketing undermines patient safety and public health. American Journal of Public Health, 101(3), 399–404. https://doi.org/https://doi.org/10.2105/AJPH.2010.199844
- Campbell, S. (2009). Promotional Spending for Prescription Drugs. Congressional Budget Office. https://www.cbo.gov/sites/default/files/111th-congress-2009-2010/reports/12-02-drugpromo_brief.pdf
- Chakrabarty, S., & Bass, A. E. (2013). Comparing virtue, consequentialist, and deontological ethics-based corporate social responsibility: Mitigating microfinance risk in institutional voids. Journal of Business Ethics, 126(3), 487–512. https://doi.org/https://doi.org/10.1007/s10551-013-1963-0
- Chiplunkar, S., Gowda, D., & Shivakumar, H. (2020). Adaptation of pharmaceutical marketing and drug promotion practices in times of pandemic COVID-19. International Journal of Health & Allied Sciences, 9(5), 11–11.
- Coleman, J. B. (2017). Fairness and respect in marketing. In A. J. G. Sison, G. R. Beabout, & I. Ferrero (Eds.), Handbook of Virtue Ethics in Business and Management (pp. 1047–1056). Springer. https://doi.org/https://doi.org/10.1007/978-94-007-6510-8_87
- Costa, T., Tiago, T., Tiago, F., Faria, S., & Couto, J. (2017). Pharmaceutical marketing STAR. In A. Kavoura, D. P. Sakas, & P. Tomaras (Eds.), Strategic innovative marketing (pp. 173–178). Springer.
- Cressey, D. (2007, September 12). ‘Hippocratic oath for scientists’: News blog. Nature NewsBlog. http://blogs.nature.com/news/2007/09/hippocratic_oath_for_scientist.html
- Dahl, S., & Eagle, L. (2016). Empowering or misleading? Online health information provision challenges. Marketing Intelligence & Planning, 34(7), 1000–1020. https://doi.org/https://doi.org/10.1108/MIP-07-2015-0127
- Darmawan, I. (2020). Unbranded vs. branded direct-to-consumer advertising (dtca) using social media influencers: Examining the effects of message type and disclosure. http://conservancy.umn.edu/handle/11299/214985
- Donohue, J. (2006). A history of drug advertising: the evolving roles of consumers and consumer protection. The Milbank Quarterly, 84(4), 659–699. https://doi.org/https://doi.org/10.1111/j.1468-0009.2006.00464.x
- Dunfee, T. W., Smith, N. C., & Ross, W. T. (1999). Social contracts and marketing ethics. Journal of Marketing, 63(3), 14–32. https://doi.org/https://doi.org/10.2307/1251773
- Eagle, L., & Dahl, S. (2016). Guest editorial. Marketing Intelligence & Planning, 34(7), 902–904. https://doi.org/https://doi.org/10.1108/MIP-06-2016-0090
- Ebeling, M. (2011). Get with the Program!’: Pharmaceutical marketing, symptom checklists and self-diagnosis. Social Science & Medicine (1982), 73(6), 825–832. https://doi.org/https://doi.org/10.1016/j.socscimed.2011.05.054
- Eli Lilly Canada Inc. (2011). 40over40 (Deactivated). www.40over40.ca
- Enovid®. (1962). Enovid advertisement. Obstetrics & Gynecology, 19, 114–115.
- Enyinda, C. I., Ogbuehi, A. O., & Mbah, C. H. (2018). Building pharmaceutical relationship marketing and social media impact: An empirical analysis. International Journal of Pharmaceutical and Healthcare Marketing, 12(2), 198–230. https://doi.org/https://doi.org/10.1108/IJPHM-02-2017-0007
- Feldman, Y., Gauthier, R., & Schuler, T. (2013). Curbing misconduct in the pharmaceutical industry: Insights from behavioral ethics and the behavioral approach to law. The Journal of Law, Medicine & Ethics, 41(3), 620–628. https://doi.org/https://doi.org/10.1111/jlme.12071
- Ferrell, O. C., & Gresham, L. G. (1985). A contingency framework for understanding ethical decision making in marketing. Journal of Marketing, 49(3), 87–96. https://doi.org/https://doi.org/10.2307/1251618
- Filho, E. J. M. A., & Barcelos, A. d A. (2021). Negative online word-of-mouth: Consumers’ retaliation in the digital world. Journal of Global Marketing, 34(1), 19–37. https://doi.org/https://doi.org/10.1080/08911762.2020.1775919
- Fort, T. L. (2014). The paradox of pharmaceutical CSR: The sincerity nexus. Business Horizons, 57(2), 151–160. https://doi.org/https://doi.org/10.1016/j.bushor.2013.10.006
- Freudenberg, N. (2005). Public health advocacy to change corporate practices: Implications for health education practice and research. Health Education & Behavior, 32(3), 298–319. https://doi.org/https://doi.org/10.1177/1090198105275044
- Freudenberg, N., & Galea, S. (2008). The impact of corporate practices on health: Implications for health policy. Journal of Public Health Policy, 29(1), 86–104. https://doi.org/https://doi.org/10.1057/palgrave.jphp.3200158
- Glasier, A. F., Smith, K. B., van der Spuy, Z. M., Ho, P. C., Cheng, L., Dada, K., Wellings, K., & Baird, D. T. (2003). Amenorrhea associated with contraception—An international study on acceptability. Contraception, 67(1), 1–8. https://doi.org/https://doi.org/10.1016/S0010-7824(02)00474-2
- Habes, M., Alnaser, A., Alghizzawi, M., Ali, S., & Salloum, S. (2020). The relation among marketing ads, via digital media and mitigate (COVID-19) pandemic in Jordan. Nternational Journal of Advanced Science and Technology, 29(7), 12326–12348.
- Haque, O. S., De Freitas, J., Bursztajn, H. J., Cosgrove, L., Gopal, A. A., Paul, R., Shuv-Ami, I., & Wolfman, S. (2013). The ethics of pharmaceutical industry influence in medicine. UNESCO.
- Harker, D. (1998). Achieving acceptable advertising: An analysis of advertising regulation in five countries. International Marketing Review, 15(2), 101–118. https://doi.org/https://doi.org/10.1108/02651339810212476
- Harker, M., & Harker, D. (2007). Direct-to-consumer advertising of prescription medicines: A systematic review of the evidence from the perspective of the consumer. Journal of Medical Marketing, 7(1), 45–54. https://doi.org/https://doi.org/10.1057/palgrave.jmm.5050060
- Herxheimer, A., & Collier, J. (1990). Promotion by the British pharmaceutical industry, 1983-8: A critical analysis of self regulation. BMJ, 300(6720), 307–311. https://doi.org/https://doi.org/10.1136/bmj.300.6720.307
- Hoppe, H.-H. (2017). The ethics of entrepreneurship and profit. In A. J. G. Sison, G. R. Beabout, & I. Ferrero (Eds.), Handbook of Virtue Ethics in Business and Management (pp. 415–422). Springer. https://doi.org/https://doi.org/10.1007/978-94-007-6510-8_21
- Huhmann, B. A., & Limbu, Y. B. (2016). Content and compliance of pharmaceutical social media marketing. Marketing Intelligence & Planning, 34(7), 977–999. https://doi.org/https://doi.org/10.1108/MIP-06-2015-0124
- Hulkower, R. (2016). The history of the hippocratic oath: outdated, inauthentic, and yet still relevant. Einstein Journal of Biology and Medicine, 25(1), 41–44. https://doi.org/https://doi.org/10.23861/EJBM20102542
- Hunt, S. D., & Vitell, S. (1986). A general theory of marketing ethics. Journal of Macromarketing, 6(1), 5–16. https://doi.org/https://doi.org/10.1177/027614678600600103
- Johnston-Robledo, I., Barnack, J., & Wares, S. (2006). Kiss your period good-bye”: Menstrual suppression in the popular press. Sex Roles, 54(5-6), 353–360. https://doi.org/https://doi.org/10.1007/s11199-006-9007-1
- Jones, I. R., & Higgs, P. F. (2010). The natural, the normal and the normative: Contested terrains in ageing and old age. Social Science & Medicine (1982), 71(8), 1513–1519. https://doi.org/https://doi.org/10.1016/j.socscimed.2010.07.022
- Junod, S. W., & Marks, L. (2002). Women’s trials: The approval of the first oral contraceptive pill in the United States and Great Britain. Journal of the History of Medicine and Allied Sciences, 57(2), 117–160. https://doi.org/https://doi.org/10.1093/jhmas/57.2.117
- Katsanis, L. P. (2016). Global issues in pharmaceutical marketing. Routledge.
- Khan, M. R., & Basak, K. (2021). Shifts in pharma-marketing trends in post COVID-19 era. International Journal of Multidisciplinary: Applied Business and Education Research, 2(2), 172–178.
- Koehn, D. (1995). A role for virtue ethics in the analysis of business practice. Business Ethics Quarterly, 5(3), 533–539. https://doi.org/https://doi.org/10.2307/3857397
- Laczniak, G. R., & Murphy, P. E. (1993). Ethical marketing decisions: The higher road. Allyn & Bacon.
- Laczniak, G. R., & Murphy, P. E. (2006). Normative perspectives for ethical and socially responsible marketing. Journal of Macromarketing, 26(2), 154–177. https://doi.org/https://doi.org/10.1177/0276146706290924
- LEO Pharma. (2017). Annual Report 2016 (CVR no. 56 75 95 14).
- Liberati, C., & Mariani, P. (2018). Big data meet pharmaceutical industry: An application on social media data. In F. Mola, C. Conversano, & M. Vichi (Eds.), Classification, (Big) Data Analysis and Statistical Learning (pp. 23–30). Springer International Publishing. https://doi.org/https://doi.org/10.1007/978-3-319-55708-3_3
- Lipworth, W., & Little, M. (2014). Deriving and critiquing an empirically based framework for pharmaceutical ethics. AJOB Empirical Bioethics, 5(1), 23–32. https://doi.org/https://doi.org/10.1080/21507716.2013.812690
- Lipworth, W., Montgomery, K., & Little, M. (2013). How pharmaceutical industry employees manage competing commitments in the face of public criticism. Journal of Bioethical Inquiry, 10(3), 355–367. https://doi.org/https://doi.org/10.1007/s11673-013-9449-4
- Lury, C., & Day, S. (2019). Algorithmic personalization as a mode of individuation. Theory, Culture & Society, 36(2), 17–37. https://doi.org/https://doi.org/10.1177/0263276418818888
- Luu, D. T. (2020). The effect of internal corporate social responsibility practices on pharmaceutical firm’s performance through employee intrapreneurial behaviour. Journal of Organizational Change Management, 33(7), 1375–1400. https://doi.org/https://doi.org/10.1108/JOCM-03-2020-0072
- Mackenzie, F. J., Jordens, C. F., Ankeny, R. A., McPhee, J., & Kerridge, I. H. (2007). Direct-to-consumer advertising under the radar: The need for realistic drugs policy in Australia. Internal Medicine Journal, 37(4), 224–228. https://doi.org/https://doi.org/10.1111/j.1445-5994.2006.01298.x
- Mamo, L., & Fosket, J. R. (2009). Scripting the body: Pharmaceuticals and the (re)making of menstruation. Signs, 34(4), 925–949. https://doi.org/https://doi.org/10.1086/597191
- Marshall, B. L. (2010). Science, medicine and virility surveillance: ‘sexy seniors’ in the pharmaceutical imagination. Sociology of Health & Illness, 32(2), 211–224. https://doi.org/https://doi.org/10.1111/j.1467-9566.2009.01211.x
- Martin, T. R. (1985). Ethics in marketing: Problems and prospects. In G. R. Laczniak & P. E. Murphy (Eds.), Marketing ethics: Guidelines for managers (pp. 1–8). Lexington Books.
- McCaffrey, K. (2017a, March 3). Drugmakers again boost DTC spending, to $5.6 billion in 2016. MM&M. http://www.mmm-online.com/commercial/drugmakers-again-boost-dtc-spending-to-56-billion-in-2016/article/642028/
- McCaffrey, K. (2017b, May 16). Califf calls for marketers to develop off-label “code of ethics.” MM&M.http://www.mmm-online.com/legalregulatory/fda-off-label-promotion-califf-marketing-advertising-pharma/article/661852/
- Mintzes, B. (2006). Disease mongering in drug promotion: Do governments have a regulatory role?PLoS Medicine, 3(4), e198–e465. https://doi.org/https://doi.org/10.1371/journal.pmed.0030198
- Mintzes, B. (2009). Should Canada allow direct-to-consumer advertising of prescription drugs? NO. Canadian Family Physician, 55(2), 131–133.
- Mulinari, S. (2016). Regulating pharmaceutical industry marketing: development, enforcement, and outcome of marketing rules. Sociology Compass, 10(1), 74–86. https://doi.org/https://doi.org/10.1111/soc4.12335
- Nantel, J., & Weeks, W. A. (1996). Marketing ethics: Is there more to it than the utilitarian approach?European Journal of Marketing, 30(5), 9–19. https://doi.org/https://doi.org/10.1108/03090569610118713
- Niquette, M. (2010). Marketing pharmaceutique et médias sociaux: Analyse critique du discours d’une page FacebookMD sur le TDA/H. Revue Internationale Sur Le Médicament, 3, 53–116.
- Niquette, M. (2012). The exploitation of” sicko-chatting” by the pharmaceutical industry: A strategy for the normalization of drug use. Communiquer Dans Un Monde de Normes. L’information et La Communication Dans Les Enjeux Contemporains de La” Mondialisation”. 296. http://hal.univ-lille3.fr/hal-00835818
- Novartis. (2017). Annual Report 2016.
- O’Neil, C. (2016). Weapons of math destruction: How big data increases inequality and threatens democracy. Crown Publishing Group (NY).
- Palmer, D. E. (2017). Conceptions and misconceptions of virtue in marketing. In A. J. G. Sison, G. R. Beabout, & I. Ferrero (Eds.), Handbook of virtue ethics in business and management (pp. 1027–1035). Springer. https://doi.org/https://doi.org/10.1007/978-94-007-6510-8_85
- Perls, T., & Handelsman, D. J. (2015). Disease mongering of age-associated declines in testosterone and growth hormone levels. Journal of the American Geriatrics Society, 63(4), 809–811. https://doi.org/https://doi.org/10.1111/jgs.13391
- Pfizer. (2017a). 2016 Annual review: Accelerating patient impact.
- Pfizer. (2017b). Sales and marketing compliance. http://www.pfizer.com/purpose/transparency/ethical-sales-and-marketing
- Rader, C. S., Subhan, Z., Lanier, C. D., Brooksbank, R., Yankah, S., & Spears, K. (2014). CyberRx: Emerging social media marketing strategy for pharmaceuticals. International Journal of Pharmaceutical and Healthcare Marketing, 8(2), 193–225. https://doi.org/https://doi.org/10.1108/IJPHM-05-2013-0027
- Rahman, M., Rodríguez-Serrano, M. Á., & Lambkin, M. (2020). Advertising efficiency and profitability: Evidence from the pharmaceutical industry. Industrial Marketing Management, 89, 619–629. https://doi.org/https://doi.org/10.1016/j.indmarman.2019.02.001
- Ramanathan, J., & Swain, B. (2017). Are marketers egoists? A typological explication. Journal of Business Ethics, 155(2), 611–611. https://doi.org/https://doi.org/10.1007/s10551-017-3515-5
- Richardson, J. (2015, January 6). Big pharma wants to date me, and other quirks of being sick in America. The Rumpus.Net. http://therumpus.net/2015/01/big-pharma-wants-to-date-me-and-other-quirks-of-being-sick-in-america/
- Robin, D., Giallourakis, M., David, F. R., & Moritz, T. E. (1989). A different look at codes of ethics. Business Horizons, 32(1), 66–73. https://doi.org/https://doi.org/10.1016/0007-6813(89)90028-1
- Sarkees, M. E., Fitzgerald, M. P., & Lamberton, C. (2021). The pandemic ripple effect: Understanding marketing and public policy opportunities in the pharmaceutical industry. Journal of Public Policy & Marketing, 40(1), 103–104. https://doi.org/https://doi.org/10.1177/0743915620930693
- Scanlon, T. M. (1998). What we owe to each other. Harvard University Press.
- Scott, M. L., Martin, K. D., Wiener, J. L., Ellen, P. S., & Burton, S. (2020). The COVID-19 pandemic at the intersection of marketing and public policy. Journal of Public Policy & Marketing, 39(3), 257–265. https://doi.org/https://doi.org/10.1177/0743915620932151
- Seshadri, S., & Broekemier, G. M. (2009). Ethical decision making: Panama–United States differences in consumer and marketing contexts. Journal of Global Marketing, 22(4), 299–311. https://doi.org/https://doi.org/10.1080/08911760903022515
- Shakespeare, J., Neve, E., & Hodder, K. (2000). Is norethisterone a lifestyle drug? Results of database analysis. BMJ (Clinical Research ed.), 320(7230), 291. https://doi.org/https://doi.org/10.1136/bmj.320.7230.291
- Shankar, V., & Li, J. (Krista). (2014). Leveraging social media in the pharmaceutical industry. In M. Ding, J. Eliashberg, & S. Stremersch (Eds.), Innovation and marketing in the pharmaceutical industry: Emerging practices, research, and policies (pp. 477–505). Springer. https://doi.org/https://doi.org/10.1007/978-1-4614-7801-0_16
- Shaw, B., & Whitney, P. (2016). Ethics and compliance in global pharmaceutical industry marketing and promotion: The role of the IFPMA and self-regulation. Pharmaceuticals Policy and Law, 18(1-4), 199–206. https://doi.org/https://doi.org/10.3233/PPL-160443
- Singer, A. E., Lysonski, S., Singer, M., & Hayes, D. (1991). Ethical myopia: The case of “framing” by framing. Journal of Business Ethics, 10(1), 29–36. https://doi.org/https://doi.org/10.1007/BF00383690
- Smith, N. C., Goldstein, D. G., & Johnson, E. J. (2013). Choice without awareness: Ethical and policy implications of defaults. Journal of Public Policy & Marketing, 32(2), 159–172. https://doi.org/https://doi.org/10.1509/jppm.10.114
- Society for Menstrual Cycle Research. (2007). New medications target menstrual suppression for healthy women and girls: “Menstruation is not a disease” say leading researchers. Canadian Women’s Health Network, 10(1), 28–29.
- Solomon, R. C. (1992). Ethics and excellence: Cooperation and integrity in business. Oxford University Press.
- Sreen, N., Purbey, S., & Sadarangani, P. (2020). Understanding the relationship between different facets of materialism and attitude toward green products. Journal of Global Marketing, 33(5), 396–416. https://doi.org/https://doi.org/10.1080/08911762.2020.1751370
- Sulak, P. J., Kuehl, T. J., Ortiz, M., & Shull, B. L. (2002). Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. American Journal of Obstetrics and Gynecology, 186(6), 1142–1149. https://doi.org/https://doi.org/10.1067/mob.2002.122988
- Teerakapibal, S. (2020). Human values and life satisfaction: Moderating effects of culture and age. Journal of Global Marketing, 33(3), 177–192. https://doi.org/https://doi.org/10.1080/08911762.2019.1683668
- Till, O. A. (2015). The Influence of Direct to Consumer Advertising of Oral Contraceptives and the Consumer’s Attitudes and Perceptions that Ensue [University of Arkansas]. http://scholarworks.uark.edu/mktguht/19/
- Van Campen, L. E., Allen, A. J., Watson, S. B., & Therasse, D. G. (2015a). A Pharmaceutical bioethics consultation service: Six-year descriptive characteristics and results of a feedback survey. AJOB Empirical Bioethics, 6(2), 53–62. https://doi.org/https://doi.org/10.1080/23294515.2014.957363
- Van Campen, L. E., Poplazarova, T., Therasse, D. G., Turik, M., Kelman, A., Rossetti, A., Chang, C., Stern, K. N., & Fortson, W, & The Biopharmaceutical Bioethics Working Group. (2021). Considerations for applying bioethics norms to a biopharmaceutical industry setting. BMC Medical Ethics, 22(1), 31. https://doi.org/https://doi.org/10.1186/s12910-021-00600-y
- Van Campen, L. E., Therasse, D. G., Klopfenstein, M., & Levine, R. J. (2015b). Development, implementation and critique of a bioethics framework for pharmaceutical sponsors of human biomedical research. Current Medical Research and Opinion, 31(11), 2071–2080. https://doi.org/https://doi.org/10.1185/03007995.2015.1087986
- Van Campen, L. E., Therasse, D. G., Klopfenstein, M., & Levine, R. J. (2015c). Eli Lilly and Company’s bioethics framework for human biomedical research. Current Medical Research and Opinion, 31(11), 2081–2093. https://doi.org/https://doi.org/10.1185/03007995.2015.1087987
- van Stekelenborg, J., Ellenius, J., Maskell, S., Bergvall, T., Caster, O., Dasgupta, N., Dietrich, J., Gama, S., Lewis, D., Newbould, V., Brosch, S., Pierce, C. E., Powell, G., Ptaszyńska-Neophytou, A., Wiśniewski, A. F. Z., Tregunno, P., Norén, G. N., & Pirmohamed, M. (2019). Recommendations for the use of social media in pharmacovigilance: Lessons from IMI WEB-RADR. Drug Safety, 42(12), 1393–1407. https://doi.org/https://doi.org/10.1007/s40264-019-00858-7
- Velo, G., & Moretti, U. (2008). Direct-to-consumer information in Europe: The blurred margin between promotion and information. British Journal of Clinical Pharmacology, 66(5), 626–628. https://doi.org/https://doi.org/10.1111/j.1365-2125.2008.03283.x
- Watkins, A., & Hill, R. P. (2011). Morality in marketing: Oxymoron or good business practice?Journal of Business Research, 64(8), 922–927. https://doi.org/https://doi.org/10.1016/j.jbusres.2011.03.009
- Watkins, E. S. (2012). How the pill became a lifestyle drug: The pharmaceutical industry and birth control in the United States Since 1960. American Journal of Public Health, 102(8), 1462–1472. https://doi.org/https://doi.org/10.2105/AJPH.2012.300706
- Weber, L. J. (2006). Profits before People?: Ethical Standards and the Marketing of Prescription Drugs. Indiana University Press. https://muse.jhu.edu/book/9200
- Weintraub, A. (2017). Direct drug marketing. SAGE Business Researcher. https://doi.org/https://doi.org/10.1177/237455680304.n1
- Wells, B. (2014, September 22). Pharma and Twitter: A happy marriage or time for a divorce? Pharmafile. http://www.pharmafile.com/news/194750/pharma-and-twitter-happy-marriage-or-time-divorce
- Williams, O. F., & Murphy, P. E. (1990). The ethics of virtue: A moral theory for marketing. Journal of Macromarketing, 10(1), 19–29. https://doi.org/https://doi.org/10.1177/027614679001000103
- Woods, C. S. (2013). Repunctuated feminism: Marketing menstrual suppression through the rhetoric of choice. Women’s Studies in Communication, 36(3), 267–287. https://doi.org/https://doi.org/10.1080/07491409.2013.829791
- Zakhem, A. J. (2017). Honesty and integrity in advertising. In A. J. G. Sison, G. R. Beabout, & I. Ferrero (Eds.), Handbook of virtue ethics in business and management (pp. 1037–1046). Springer. https://doi.org/https://doi.org/10.1007/978-94-007-6510-8_86